These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23016864)

  • 21. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis.
    Yang GW; Jiang JS; Lu WQ
    Int J Mol Sci; 2015 Oct; 16(10):24011-31. PubMed ID: 26473837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.
    Repetto M; Crimini E; Giugliano F; Morganti S; Belli C; Curigliano G
    Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1233-1252. PubMed ID: 34591728
    [No Abstract]   [Full Text] [Related]  

  • 23. Synthesis and structure-activity relationships of 7-substituted 3-(2, 6-dichlorophenyl)-1,6-naphthyridin-2(1H)-ones as selective inhibitors of pp60(c-src).
    Thompson AM; Rewcastle GW; Boushelle SL; Hartl BG; Kraker AJ; Lu GH; Batley BL; Panek RL; Showalter HD; Denny WA
    J Med Chem; 2000 Aug; 43(16):3134-47. PubMed ID: 10956222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the fibroblast growth factor receptors for the treatment of cancer.
    Lemieux SM; Hadden MK
    Anticancer Agents Med Chem; 2013 Jun; 13(5):748-61. PubMed ID: 23272905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor receptor-2 tyrosine kinases.
    Thompson AM; Delaney AM; Hamby JM; Schroeder MC; Spoon TA; Crean SM; Showalter HD; Denny WA
    J Med Chem; 2005 Jul; 48(14):4628-53. PubMed ID: 16000000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances of dual FGFR inhibitors as a novel therapy for cancer.
    Liang Q; Wang J; Zhao L; Hou J; Hu Y; Shi J
    Eur J Med Chem; 2021 Mar; 214():113205. PubMed ID: 33556787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibroblast growth factor receptor inhibitors: patent review (2015-2019).
    Marseglia G; Lodola A; Mor M; Castelli R
    Expert Opin Ther Pat; 2019 Dec; 29(12):965-977. PubMed ID: 31679402
    [No Abstract]   [Full Text] [Related]  

  • 28. Design, synthesis and biological evaluation of 5-amino-1H-pyrazole-4-carboxamide derivatives as pan-FGFR covalent inhibitors.
    Deng W; Chen X; Liang H; Song X; Xiang S; Guo J; Tu Z; Zhou Y; Chen Y; Lu X
    Eur J Med Chem; 2024 Sep; 275():116558. PubMed ID: 38870833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
    Li X; Guise CP; Taghipouran R; Yosaatmadja Y; Ashoorzadeh A; Paik WK; Squire CJ; Jiang S; Luo J; Xu Y; Tu ZC; Lu X; Ren X; Patterson AV; Smaill JB; Ding K
    Eur J Med Chem; 2017 Jul; 135():531-543. PubMed ID: 28521156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis.
    Chen Z; Tong LJ; Tang BY; Liu HY; Wang X; Zhang T; Cao XW; Chen Y; Li HL; Qian XH; Xu YF; Xie H; Ding J
    Acta Pharmacol Sin; 2019 Jun; 40(6):823-832. PubMed ID: 30487650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Specific inhibitor of FGF receptor signaling: FGF-2-mediated effects on proliferation, differentiation, and MAPK activation are inhibited by PD173074 in oligodendrocyte-lineage cells.
    Bansal R; Magge S; Winkler S
    J Neurosci Res; 2003 Nov; 74(4):486-93. PubMed ID: 14598292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and characteristics of cytotoxic fibroblast growth factor 1 conjugate for fibroblast growth factor receptor-targeted cancer therapy.
    Szlachcic A; Zakrzewska M; Lobocki M; Jakimowicz P; Otlewski J
    Drug Des Devel Ther; 2016; 10():2547-60. PubMed ID: 27563235
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors.
    Wang Y; Li L; Fan J; Dai Y; Jiang A; Geng M; Ai J; Duan W
    J Med Chem; 2018 Oct; 61(20):9085-9104. PubMed ID: 29522671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the fibroblast growth factor receptor family in cancer.
    Hallinan N; Finn S; Cuffe S; Rafee S; O'Byrne K; Gately K
    Cancer Treat Rev; 2016 May; 46():51-62. PubMed ID: 27109926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.
    Borzilleri RM; Zheng X; Qian L; Ellis C; Cai ZW; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Fura A; Kamath A; Vyas V; Tokarski JS; Barrish JC; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
    J Med Chem; 2005 Jun; 48(12):3991-4008. PubMed ID: 15943473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting fibroblast growth factor receptor pathway in breast cancer.
    Criscitiello C; Esposito A; De Placido S; Curigliano G
    Curr Opin Oncol; 2015 Nov; 27(6):452-6. PubMed ID: 26397764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors.
    Fan J; Dai Y; Shao J; Peng X; Wang C; Cao S; Zhao B; Ai J; Geng M; Duan W
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2594-9. PubMed ID: 27117427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models.
    Squires M; Ward G; Saxty G; Berdini V; Cleasby A; King P; Angibaud P; Perera T; Fazal L; Ross D; Jones CG; Madin A; Benning RK; Vickerstaffe E; O'Brien A; Frederickson M; Reader M; Hamlett C; Batey MA; Rich S; Carr M; Miller D; Feltell R; Thiru A; Bethell S; Devine LA; Graham BL; Pike A; Cosme J; Lewis EJ; Freyne E; Lyons J; Irving J; Murray C; Newell DR; Thompson NT
    Mol Cancer Ther; 2011 Sep; 10(9):1542-52. PubMed ID: 21764904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.
    Mohammadi M; Froum S; Hamby JM; Schroeder MC; Panek RL; Lu GH; Eliseenkova AV; Green D; Schlessinger J; Hubbard SR
    EMBO J; 1998 Oct; 17(20):5896-904. PubMed ID: 9774334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis and biological evaluation of N-phenylthieno[2,3-d]pyrimidin-4-amines as inhibitors of FGFR1.
    Gryshchenko AA; Bdzhola VG; Balanda AO; Briukhovetska NV; Kotey IM; Golub AG; Ruban TP; Lukash LL; Yarmoluk SM
    Bioorg Med Chem; 2015 May; 23(9):2287-93. PubMed ID: 25817240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.